新しいビスフェノールAの代替品であるDD-70は,サイクロオキシゲネーゼ1を阻害することによって,血液静止に悪影響を及ぼす可能性があります
Marcel Hrubša1, Alina Soloviova2, Catherine Gunaseelan1
1Department of Pharmacology and Toxicology, Faculty of Pharmacy, Charles University, Akademika Heyrovského 1203, 500 05 Hradec Králové, Czech Republic.
Environment international
|August 29, 2025
まとめ
ビスフェノールAの代替品は,血液への影響について試験された. 別の薬剤であるDD-70は,サイクロオキシゲネーゼ1を阻害することで強力な抗血小板活性を示した.
科学分野:
- 環境毒性学
- 血液学
- 労働衛生について
背景:
- ビスフェノールは一般的な産業化学物質で 環境汚染物質です
- ビスフェノールA (BPA) の禁止は,生物学的効果が不明な代替品の使用につながった.
- BPAの代替物の健康への影響に関するデータは限られている.
研究 の 目的:
- 4種類のBPAの代替品がヒトと動物の血液静止と赤血球に与える潜在的な悪影響を調査する.
- これらの化合物の急性毒性,血小板結束,血液凝固効果を評価する.
主な方法:
- ラットとヒトの細胞における乳酸脱水素酵素測定を用いて評価された赤血球毒性.
- 作用メカニズム分析を含む全人血液における血小板の集積を研究した.
- 血液凝固のパラメータを評価した.
主要な成果:
- すべての試験化合物の赤血球毒性は低かった (TC50 > 500 μM).
- DD-70は,サイクロオキシゲナーゼ1を阻害することで強力な抗血小板活性 (IC50=5. 0 ±2. 7μM) を示した.
- 試験された代替品の高濃度 (≥100μM) は血液凝固に影響を与えました.
結論:
- DD-70の強力な抗血小板効果は,臨床および職業健康への影響をさらに調査する必要があります.
- この研究では,BPAの代替品の血液静止に関する潜在的なリスクが強調され,ヒトへの暴露に関する研究が必要となった.
- BPAの代用品に関する知識の欠如は,公衆衛生と環境への重大な懸念を引き起こしています.
関連する概念動画
Disorders of Hemostasis
1.2K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
1.2K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
644
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
644
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
595
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
595
Anticoagulant Drugs: Low-Molecular-Weight Heparins
889
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
889
Extrinsic and Intrinsic Pathways of Hemostasis
9.2K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
9.2K


